U.S. Plasmid DNA Manufacturing Market Size, Companies & Industry Research
The U.S. plasmid DNA manufacturing market size was valued at USD 711.90 million in 2023 and is projected to surpass around USD 4,885.15 million by 2033, registering a CAGR of 21.24% over the forecast period of 2024 to 2033.
This can be attributed to advanced innovative manufacturing technologies adoption for production and rising engagement of key market players in research and product development in gene & cell therapy. In addition, homegrown companies are expanding their manufacturing facilities in the country as well.
Furthermore, along with established Contract Development and Manufacturing (CDMOs) in the country, several new manufacturing service providers are entering the market space. This is anticipated to further boost market growth in the country. Entry of new players coupled with the expansion of facilities by existing players has intensified the competition in the U.S. market. U.S. accounted for 38% of the U.S. plasmid DNA manufacturing market in 2023 owing to the presence of key market players, including CDMOs offering GMP manufacturing services. Moreover, considering the future scope and significance of gene therapy in human disease treatment, numerous companies in the U.S. are adopting various strategic initiatives to broaden their product portfolio.
These key players are focused on the development, maturation, and implementation of innovative technologies for cell therapy manufacturing. Moreover, supportive government legislation and favorable regulatory scenarios for gene therapies in the country are anticipated to fuel the demand for plasmid DNAs. For instance, in October 2021, the U.S. FDA, NIH, and 10 pharmaceutical companies partnered to develop advanced gene therapies for rare genetic disorders. Such initiatives are likely to accelerate the demand for plasmid DNA as they have an important role in advanced therapeutics.
The demand for plasmid DNA in various medical therapies has been steadily increasing in recent years. Researchers are also focusing on the development of gene-based therapies for various diseases such as cancer and genetic disorders. Although the number of patients receiving gene therapies is less, the future of gene therapy holds great potential as it is expected to revolutionize the treatment regime by targeting the genes responsible for disease pathogenesis. As gene therapy continues to show promising results in clinical trials, the demand for plasmid DNA for research and therapeutic purposes is expected to grow.
| Report Attribute | Details |
| Market Size in 2024 | USD 863.11 Million |
| Market Size by 2033 | USD 4,885.15 Million |
| Growth Rate From 2024 to 2033 | CAGR of 21.24% |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | Grade, development phase, application, disease |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Key Companies Profiled | Charles River Laboratories; VGXI, Inc.; Danaher (Aldevron); Kaneka Corp.; Nature Technology; Cell and Gene Therapy Catapult; Eurofins Genomics; Lonza; Luminous BioSciences, LLC; Akron Biotech |
The cell & gene therapy segment held the largest market share of 55.43% in 2023 owing to wide adoption of gene therapy for treating several genetically inherited diseases. Cell & gene therapy-based medicines are increasingly being adopted owing to the advent of next-generation transfer vectors and plasmid DNA technology.
The DNA vaccines segment is expected to witness the fastest CAGR from 2024 to 2033. The demand for these is rising due to its easy manufacturing process and can be accomplished along with manufacture of other traditional vaccines in large manufacturing units. Several plasmid DNA & viral vectors are being investigated for human use owing to their advantages. These are further being explored to assess potential and thereby accelerate the development of vaccines.
The cancer segment held the largest market share of 42.09% in 2023 owing to the rising number of cancer cases in the U.S. due to poor diet choices, high consumption of alcohol, smoking, and physical inactivity. Although various cancer therapies have been proven efficacious, cancer deaths account for the majority of mortality cases.
The genetic disorder segment is expected to register a considerable CAGR from 2024 to 2033. There are many private & public companies in the U.S. focusing on this disease segment for the development of advanced gene therapy. More than 1500 ongoing clinical trials are directed toward the same in the U.S., making gene therapy for genetic disorders a very crucial segment for the market during forecast period.
The clinical therapeutics segment held the largest market share of 55.32% in 2023. Genetic vaccination techniques and personalized treatment lines have increased the importance of plasmid DNA in clinical research activities. In addition, many therapies are under clinical trials for treatment of life-threatening diseases, such as HIV, HPV, and cancer. For instance, in October 2022, Ludwig Institute for Cancer Research completed phase I clinical trial of NY-ESO-1 Plasmid DNA for treatment of bladder, prostate, esophageal, and non-small cell lung cancer, and sarcomas.
The pre-clinical segment is expected to witness the fastest CAGR from 2024 to 2033. During the R&D stages, plasmid DNA is broadly utilized in pre-clinical trials for developing toxicology or bio-distribution studies. Thus, the market for pre-clinical plasmid DNA therapeutics is expected to witness significant growth over the forecast period, owing to broad development pipeline for gene therapy and vaccines.
The GMP grade segment held the largest market share of 86.00% in 2023 owing to an increasing number of clinical developments of cell & gene therapy and DNA vaccines and continuous approvals of newly marketed therapies. Furthermore, multiple regulations have been laid down for GMP manufacturing of plasmids, which further support advanced therapy developers.
The R&D grade segment is expected to witness the fastest CAGR from 2024 to 2033. Plasmid DNA has gained immense attention due to rising demand and wide applications. Vast applications of R&D grade plasmid DNA generate high demand for this product in research settings and also in drug development & discovery fields by therapy developers. Manufacturing facility and technology advancements are expected to drive the adoption rate of R&D-grade pDNAs over the forecast period.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the U.S. Plasmid DNA Manufacturing market.
By Grade
By Development Phase
By Application
By Disease
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers